CO2017009061A2 - Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenes - Google Patents
Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenesInfo
- Publication number
- CO2017009061A2 CO2017009061A2 CONC2017/0009061A CO2017009061A CO2017009061A2 CO 2017009061 A2 CO2017009061 A2 CO 2017009061A2 CO 2017009061 A CO2017009061 A CO 2017009061A CO 2017009061 A2 CO2017009061 A2 CO 2017009061A2
- Authority
- CO
- Colombia
- Prior art keywords
- pyogenes
- variant polypeptides
- degradation enzyme
- igg
- immunoglobulin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
La presente invención se refiere a un polipéptido novedoso que exhibe actividad de proteasa de cisteína de IgG y usos in vivo y ex vivo de los mismos. Usos del polipéptido incluyen métodos para la prevención o tratamiento de enfermedades y afecciones mediadas por IgG, y métodos para el análisis de IgG.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201502306A GB201502306D0 (en) | 2015-02-12 | 2015-02-12 | Protein |
| PCT/EP2016/053052 WO2016128558A1 (en) | 2015-02-12 | 2016-02-12 | Cysteine protease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017009061A2 true CO2017009061A2 (es) | 2018-01-16 |
Family
ID=52781456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0009061A CO2017009061A2 (es) | 2015-02-12 | 2017-09-04 | Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenes |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10696959B2 (es) |
| EP (2) | EP4108768A1 (es) |
| JP (1) | JP6961486B2 (es) |
| KR (1) | KR102524613B1 (es) |
| CN (2) | CN114231512A (es) |
| AU (2) | AU2016217800B2 (es) |
| BR (1) | BR112017017284A2 (es) |
| CA (1) | CA2976003A1 (es) |
| CL (1) | CL2017002065A1 (es) |
| CO (1) | CO2017009061A2 (es) |
| DK (1) | DK3256580T3 (es) |
| EA (1) | EA035130B1 (es) |
| ES (1) | ES2927234T3 (es) |
| GB (1) | GB201502306D0 (es) |
| IL (1) | IL253938B (es) |
| LT (1) | LT3256580T (es) |
| MX (1) | MX2017010390A (es) |
| MY (1) | MY188696A (es) |
| PL (1) | PL3256580T3 (es) |
| PT (1) | PT3256580T (es) |
| SG (1) | SG11201706346QA (es) |
| WO (1) | WO2016128558A1 (es) |
| ZA (1) | ZA201705113B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201502306D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| WO2019195449A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Antibody-evading virus vectors |
| AR118465A1 (es) | 2019-03-21 | 2021-10-06 | Stridebio Inc | Vectores de virus adenoasociados recombinantes |
| WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| MX2022004352A (es) | 2019-10-17 | 2022-07-19 | Stridebio Inc | Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c. |
| MY190626A (en) | 2019-12-06 | 2022-04-27 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
| JP2023514204A (ja) | 2020-02-14 | 2023-04-05 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | Ｃｄｋｌ５欠損障害を処置するための遺伝子治療 |
| GB202002072D0 (en) | 2020-02-14 | 2020-04-01 | Hansa Biopharma AB | immunoglobulin detection and associated therapies |
| GB202003129D0 (en) | 2020-03-04 | 2020-04-15 | Hansa Biopharma AB | Conditioning regimen for transplant of stem cells |
| GB202007434D0 (en) | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
| GB202007431D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
| WO2021244628A1 (zh) | 2020-06-05 | 2021-12-09 | 上海宝济药业有限公司 | 一种酶和病毒的药物组合及其应用 |
| CN115443288A (zh) * | 2020-06-18 | 2022-12-06 | 上海宝济药业有限公司 | 一种免疫球蛋白降解酶IdeE的突变体 |
| IL301955A (en) | 2020-10-07 | 2023-06-01 | Asklepios Biopharmaceutical Inc | Therapeutic delivery of an adeno-related protein-related protein (FKRP) virus for the treatment of dystroglycanopathy disorders, including limb girdle 21 |
| JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| WO2023019168A1 (en) | 2021-08-11 | 2023-02-16 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating a muscular dystrophy |
| CA3237815A1 (en) | 2021-11-15 | 2023-05-19 | Raghuveer RANGANATHAN | Methods for enhancing adoptive cell transfer immunotherapies |
| WO2023116817A1 (zh) * | 2021-12-22 | 2023-06-29 | 上海宝济药业有限公司 | 一种免疫球蛋白降解酶IdeE的突变体的用途 |
| EP4275701A1 (en) | 2022-05-13 | 2023-11-15 | Hansa Biopharma AB | Conditioning regimen for cell transplant |
| EP4302770A1 (en) | 2022-07-08 | 2024-01-10 | Hansa Biopharma AB | Regimen for enzymatic desensitisation |
| EP4349365A1 (en) | 2022-10-07 | 2024-04-10 | Hansa Biopharma AB | Co-treatment for gene therapy |
| CN115873833A (zh) * | 2022-11-08 | 2023-03-31 | 上海泰昶生物技术有限公司 | 生产免疫球蛋白g降解酶的工程菌株和工艺 |
| CN115998690A (zh) * | 2022-11-10 | 2023-04-25 | 上海泰昶生物技术有限公司 | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US6800744B1 (en) * | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| AU1686302A (en) | 2000-12-21 | 2002-07-01 | Shire Biochem Inc | Streptococcus pyogenes antigens and corresponding dna fragments |
| GB0130228D0 (en) * | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
| AU2004218284B2 (en) * | 2003-03-04 | 2009-07-23 | Intercell Ag | Streptococcus pyogenes antigens |
| US8133483B2 (en) * | 2005-06-09 | 2012-03-13 | Hansa Medical Ab | Method of treating or preventing a disease or condition mediated by pathogenic IgG antibodies |
| GB0511769D0 (en) * | 2005-06-09 | 2005-07-20 | Hansa Medical Ab | Treatment |
| US7544577B2 (en) * | 2005-08-26 | 2009-06-09 | International Business Machines Corporation | Mobility enhancement in SiGe heterojunction bipolar transistors |
| CN101889082A (zh) | 2007-09-14 | 2010-11-17 | 季诺维斯公司 | 用于解离Fcgamma-受体-IgG复合物以及纯化与检测IgG的方法和试剂盒 |
| CN102026658A (zh) * | 2007-12-13 | 2011-04-20 | 英特瓦克公司 | 改进的免疫组合物 |
| WO2009080278A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Stability testing of antibodies |
| WO2010089126A2 (en) | 2009-02-09 | 2010-08-12 | Roche Glycart Ag | Immunoglobulin glycosylation pattern analysis |
| ES2612520T3 (es) | 2010-05-26 | 2017-05-17 | Intervacc Ab | Vacuna contra infecciones estreptocócicas basada en proteínas recombinantes |
| GB201115841D0 (en) * | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| GB201201314D0 (en) | 2012-01-26 | 2012-03-07 | Isis Innovation | Composition |
| CN103214549B (zh) * | 2013-01-15 | 2015-08-05 | 珠海市丽珠单抗生物技术有限公司 | 一种还原免疫球蛋白的方法及其试剂盒 |
| GB201316744D0 (en) | 2013-09-20 | 2013-11-06 | Genovis Ab | Method |
| GB201413240D0 (en) | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502306D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
-
2015
- 2015-02-12 GB GB201502306A patent/GB201502306D0/en not_active Ceased
-
2016
- 2016-02-12 ES ES16707653T patent/ES2927234T3/es active Active
- 2016-02-12 CN CN202111557859.9A patent/CN114231512A/zh active Pending
- 2016-02-12 MX MX2017010390A patent/MX2017010390A/es unknown
- 2016-02-12 BR BR112017017284A patent/BR112017017284A2/pt not_active Application Discontinuation
- 2016-02-12 PL PL16707653.8T patent/PL3256580T3/pl unknown
- 2016-02-12 US US15/550,309 patent/US10696959B2/en active Active
- 2016-02-12 KR KR1020177025560A patent/KR102524613B1/ko active IP Right Grant
- 2016-02-12 CN CN201680021601.8A patent/CN107532156A/zh active Pending
- 2016-02-12 CA CA2976003A patent/CA2976003A1/en active Pending
- 2016-02-12 MY MYPI2017001124A patent/MY188696A/en unknown
- 2016-02-12 PT PT167076538T patent/PT3256580T/pt unknown
- 2016-02-12 EP EP22174919.5A patent/EP4108768A1/en active Pending
- 2016-02-12 WO PCT/EP2016/053052 patent/WO2016128558A1/en active Application Filing
- 2016-02-12 EA EA201791773A patent/EA035130B1/ru not_active IP Right Cessation
- 2016-02-12 EP EP16707653.8A patent/EP3256580B1/en active Active
- 2016-02-12 LT LTEPPCT/EP2016/053052T patent/LT3256580T/lt unknown
- 2016-02-12 JP JP2017542896A patent/JP6961486B2/ja active Active
- 2016-02-12 SG SG11201706346QA patent/SG11201706346QA/en unknown
- 2016-02-12 DK DK16707653.8T patent/DK3256580T3/da active
- 2016-02-12 AU AU2016217800A patent/AU2016217800B2/en active Active
-
2017
- 2017-07-27 ZA ZA2017/05113A patent/ZA201705113B/en unknown
- 2017-08-10 IL IL253938A patent/IL253938B/en active IP Right Grant
- 2017-08-11 CL CL2017002065A patent/CL2017002065A1/es unknown
- 2017-09-04 CO CONC2017/0009061A patent/CO2017009061A2/es unknown
-
2020
- 2020-05-20 US US16/879,324 patent/US11214784B2/en active Active
-
2021
- 2021-11-11 AU AU2021266293A patent/AU2021266293A1/en active Pending
- 2021-12-14 US US17/644,315 patent/US11667905B2/en active Active
-
2023
- 2023-05-16 US US18/318,455 patent/US20230357741A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017009061A2 (es) | Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenes | |
| CO2017009060A2 (es) | Polipéptido hibrido de la enzima de degradación inmunoglobulina g del s. pyogenes y enzima de degradación de inmunoglobulina g del streptococcus equi ssp. zooepidemicus | |
| EA201792583A1 (ru) | Способы и композиции для ингибирования взаимодействия менина с белками mll | |
| GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
| CL2019000261A1 (es) | Polipéptidos modificados y usos de los mismos. | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CL2018001384A1 (es) | Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales | |
| EA201791867A1 (ru) | Бициклические гетероциклы как ингибиторы fgfr4 | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| BR112016028891A2 (pt) | processos de trens de sementes e usos dos mesmos | |
| UY36905A (es) | Anticuerpos neutralizantes de poliomavirus | |
| EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| CR20160561A (es) | Variantes del anticuerpo anti-factor d y sus usos | |
| BR112019004785A2 (pt) | variantes de alfa-glicosidase ácida e usos das mesmas | |
| PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
| BR112019004783A2 (pt) | variantes de alfa-glicosidase ácida e usos das mesmas | |
| ECSP17003946A (es) | Anticuerpos antagonistas del interferón alfa y omega | |
| BR112018002382A2 (pt) | novos anticorpos anti-gvpi humano e usos dos mesmos | |
| BR112016019389A8 (pt) | Vacina, e, peptídeo | |
| CO2017001387A2 (es) | Proceso para purificación de rhu-gcsf | |
| BR112017024908A2 (pt) | usos terapêuticos da 4-cloroquinurenina | |
| CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| BR112018077458A2 (pt) | proteases aspárticas | |
| CL2019000702A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos. |